Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 111
Filtrer
1.
Pancreatology ; 21(5): 862-869, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-33846092

RÉSUMÉ

OBJECTIVES: Severe acute pancreatitis (SAP) has high morbidity and mortality but there are no widely accepted predictive biomarkers in clinical use. Matrix metalloproteinases (MMPs) are active in tissue destruction and inflammatory responses. We studied whether serum levels of activated MMP-8 (aMMP-8), MMP-9 and their regulators tissue inhibitor of matrix metalloproteinases (TIMP)-1, myeloperoxidase (MPO) and human neutrophil elastase (HNE) could predict the development of SAP. METHODS: The study comprised 214 AP patients (revised Atlanta classification: 142 mild, MAP; 54 moderately severe, MSAP; 18 SAP) referred to Helsinki University Hospital. A venous blood sample was taken within 72 h from the onset of symptoms. Serum levels of aMMP-8 were determined using immunofluorometric assay, and those of MMP-9, TIMP-1, MPO and HNE using enzyme-linked immunosorbent assay. AP groups were compared using Jonckheere-Terpstra test and predictive value for SAP was analyzed using receiver operating characteristics (ROC) analysis. RESULTS: Serum aMMP-8 levels were higher in SAP (median 657 ng/ml, interquartile range 542-738 ng/ml) compared to MSAP (358 ng/ml, 175-564 ng/ml; p < 0.001) and MAP (231 ng/ml, 128-507 ng/ml; p < 0.001). Similar trend was seen with TIMP-1 and MPO. In ROC analysis aMMP-8, MPO and TIMP-1 emerged as potential markers for the development of SAP (areas under ROC curves 0.83, 0.71 and 0.69, respectively). CONCLUSIONS: Serum aMMP-8 measured early in the course of AP (within 72 h of symptom onset) predicted the development of SAP.


Sujet(s)
Matrix metalloproteinase 8 , Pancréatite , Maladie aigüe , Marqueurs biologiques , Humains , Matrix metalloproteinase 9 , Inhibiteur tissulaire de métalloprotéinase-1
2.
Scand J Surg ; 109(1): 53-58, 2020 Mar.
Article de Anglais | MEDLINE | ID: mdl-32192420

RÉSUMÉ

BACKGROUND: Acute pancreatitis is a common disease, the incidence of which is 75-100/100,000/year in Finland. The worldwide incidence of acute pancreatitis is increasing. The identified mildcases usually show rapid recovery with conservative treatment allowing early discharge. Severe cases need early intensive care to reduce the risk of serious complications such as multi-organ failure. The revised Atlanta classification of acute pancreatitis was introduced in 2012-2013. A recurrent acute pancreatitis is defined as two or more well-documented separate attacks of acute pancreatitis with complete resolution in between. Alcoholic pancreatitis is the most common recurrent acute pancreatitis type. METHODS: In this review current severity classifications and literature on the prevention of recurrent acute pancreatitis are analyzed. RESULTS: The severity of the disease is classified as mild, moderately severe, and severe acute pancreatitis. Novel entities include acute peripancreatic fluid collections in mild acute pancreatitis and acute necrotic collections in necrotizing acute pancreatitis lesser than 4 weeks after the onset and pancreatic pseudocyst in mild acute pancreatitis and walled-off necrosis in necrotizing acute pancreatitis more than 4 weeks after the onset of the disease. After the first attack of alcohol-induced acute pancreatitis, 46% of the patients develop at least one recurrence within 10- to 20-year follow-up. With repeated intervention against alcohol consumption, it is possible to reduce the recurrences. Removing the gall bladder after biliary pancreatitis is the key preventing recurrences. In mild cases, even during the index admission; in severe cases, it is recommended to wait until the inflammatory changes have resolved. Of total, 59% of the idiopathic pancreatitis had sludge of stones in the gall bladder. In other etiologies, addressing the etiological factor may prevent recurrent acute pancreatitis. CONCLUSIONS: This review describes current use of novel severity classifications and also different possibilities to prevent recurrent acute pancreatitis with different etiologies including idiopathic.


Sujet(s)
Pancréatite/diagnostic , Humains , Pancréatite/classification , Pancréatite/étiologie , Pancréatite/prévention et contrôle , Prévention secondaire , Indice de gravité de la maladie
3.
Scand J Immunol ; 87(2): 88-98, 2018 Feb.
Article de Anglais | MEDLINE | ID: mdl-29193197

RÉSUMÉ

Intracellular signalling in blood leucocytes shows multiple aberrations in acute pancreatitis (AP) complicated by organ dysfunction (OD). We studied whether the aberrations associate with severity of AP and occur in sepsis complicated by OD. The study comprises 14 sepsis patients (11 with shock), 18 AP patients (nine mild; six moderately severe; three severe) and 28 healthy volunteers. Within 48 h after admission to hospital, phosphorylation of nuclear factor-ĸB (NF-ĸB), signal transducers and activators of transcription (STATs) 1,3, and extracellular signal-regulated kinases 1/2 were measured from stimulated or non-stimulated leucocytes using phosphospecific whole blood flow cytometry. In sepsis, as compared with healthy subjects, phosphorylated NF-ĸB levels of monocytes promoted by bacterial lipopolysaccharides, tumour necrosis factor or Escherichia coli cells were lower (P < 0.001 for all), pSTAT1 levels of monocytes promoted by IL-6 were lower (P < 0.05 for all), and STAT3 was constitutively phosphorylated in monocytes, neutrophils and lymphocytes (P < 0.001 for all). In AP, severity was associated with proportions of pSTAT1-positive monocytes and lymphocytes promoted by IL-6 (P < 0.01 for both), constitutive STAT3 phosphorylation in neutrophils (P < 0.05), but not with any of the pNF-ĸB levels. Monocyte pSTAT3 fluorescence intensity, promoted by IL-6, was lower in sepsis and AP patients with OD than in AP patients without OD (P < 0.001). Collectively, signalling aberrations in sepsis with OD mimic those described previously in AP with OD. Possibility that aberrations in STAT1 and STAT3 pathways provide novel markers predicting evolution of OD warrants studies including patients presenting without OD but developing it during follow-up.


Sujet(s)
Infections à Escherichia coli/immunologie , Escherichia coli/immunologie , Agranulocytes/immunologie , Pancréatite aigüe nécrotique/immunologie , Sepsie/immunologie , Adulte , Sujet âgé , Marqueurs biologiques/métabolisme , Cellules cultivées , Évolution de la maladie , Femelle , Humains , Lipopolysaccharides/immunologie , Mâle , Adulte d'âge moyen , Scores de dysfonction d'organes , Pancréatite aigüe nécrotique/diagnostic , Pronostic , Facteur de transcription STAT-1/métabolisme , Facteur de transcription STAT-3/métabolisme , Sepsie/diagnostic , Transduction du signal/immunologie
4.
Clin. transl. oncol. (Print) ; 19(1): 58-66, ene. 2017. tab, graf, ilus
Article de Anglais | IBECS | ID: ibc-159119

RÉSUMÉ

Background. Clinically useful marker molecules for the progression of gastroesophageal reflux disease and Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC) are lacking. Many adenocarcinomas and inflammatory conditions exhibit increased expression of ADAMs, ‘a disintegrin and metalloproteinases’. Methods. We assessed the expression of five ADAMs (9, 10, 12, 17, 19) in three esophageal cell lines (Het-1A, OE19, OE33) by RT-PCR and Western blotting, and in human samples of normal esophagus, esophagitis, BE, Barrett’s dysplasia, and EAC by RT-PCR, and in selected samples by immunohistochemistry. Results. EAC patients showed increased mRNA expression of ADAMs 9, 12, 17 and 19, as compared to controls. At immunohistochemistry, ADAM9 and ADAM10 proteins were increased in EAC. Patient samples also showed increased mRNA expression of ADAM12 in esophagitis, of ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett’s dysplasia, as compared to controls. Two EAC cell lines showed increased ADAM9 mRNA. Conclusions. ADAM9 expression is increased in EAC. Its predecessors show increased ADAM9 mRNA expression. The importance of the alterations in ADAM expression for the development of EAC, and their use as marker molecules, warrant further studies (AU)


No disponible


Sujet(s)
Humains , Mâle , Femelle , Metalloproteases/analyse , Inhibiteur tissulaire des métalloprotéinases/analyse , Reflux duodénogastrique/enzymologie , Adénocarcinome/diagnostic , Adénocarcinome/enzymologie , Oesophage de Barrett/diagnostic , Oesophage de Barrett/enzymologie , Oesophage de Barrett/anatomopathologie , Protocoles cliniques/normes , Technique de Western/instrumentation , Technique de Western , Immunohistochimie/méthodes , Immunohistochimie , Marqueurs biologiques/analyse , ARN/analyse , Protéines ADAM/analyse
5.
Clin Transl Oncol ; 19(1): 58-66, 2017 Jan.
Article de Anglais | MEDLINE | ID: mdl-27026568

RÉSUMÉ

BACKGROUND: Clinically useful marker molecules for the progression of gastroesophageal reflux disease and Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) are lacking. Many adenocarcinomas and inflammatory conditions exhibit increased expression of ADAMs, 'a disintegrin and metalloproteinases'. METHODS: We assessed the expression of five ADAMs (9, 10, 12, 17, 19) in three esophageal cell lines (Het-1A, OE19, OE33) by RT-PCR and Western blotting, and in human samples of normal esophagus, esophagitis, BE, Barrett's dysplasia, and EAC by RT-PCR, and in selected samples by immunohistochemistry. RESULTS: EAC patients showed increased mRNA expression of ADAMs 9, 12, 17 and 19, as compared to controls. At immunohistochemistry, ADAM9 and ADAM10 proteins were increased in EAC. Patient samples also showed increased mRNA expression of ADAM12 in esophagitis, of ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett's dysplasia, as compared to controls. Two EAC cell lines showed increased ADAM9 mRNA. CONCLUSIONS: ADAM9 expression is increased in EAC. Its predecessors show increased ADAM9 mRNA expression. The importance of the alterations in ADAM expression for the development of EAC, and their use as marker molecules, warrant further studies.


Sujet(s)
Protéines ADAM/métabolisme , Adénocarcinome/métabolisme , Oesophage de Barrett/métabolisme , Marqueurs biologiques tumoraux/métabolisme , Désintégrines/métabolisme , Tumeurs de l'oesophage/métabolisme , Reflux gastro-oesophagien/métabolisme , Protéines ADAM/génétique , Adénocarcinome/génétique , Adénocarcinome/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Apoptose , Oesophage de Barrett/génétique , Oesophage de Barrett/anatomopathologie , Marqueurs biologiques tumoraux/génétique , Technique de Western , Études cas-témoins , Prolifération cellulaire , Évolution de la maladie , Désintégrines/génétique , Tumeurs de l'oesophage/génétique , Tumeurs de l'oesophage/anatomopathologie , Femelle , Études de suivi , Reflux gastro-oesophagien/génétique , Reflux gastro-oesophagien/anatomopathologie , Humains , Techniques immunoenzymatiques , Mâle , Adulte d'âge moyen , Stadification tumorale , Pronostic , ARN messager/génétique , Réaction de polymérisation en chaine en temps réel , RT-PCR , Cellules cancéreuses en culture
6.
Dig Surg ; 26(5): 378-83, 2009.
Article de Anglais | MEDLINE | ID: mdl-19923825

RÉSUMÉ

BACKGROUND: Early gastric cancer (EGC) is associated with better prognosis than advanced cancer of the stomach. Unfortunately, EGC accounts for a minority of operated gastric cancers in Europe. The aim of this study was to evaluate the clinical characteristics of EGC and the outcome after surgery. METHODS: The study group comprised 94 EGC patients having undergone surgery at Helsinki University Central Hospital between April 1983 and July 2007. RESULTS: The overall 5-year survival rate of EGC patients was 92.4%. Tumor location in the upper part of the stomach and mixed histological type impaired the prognosis (p = 0.043 and 0.008, respectively). The probability of lymph node metastasis was significantly higher when the tumor infiltrated gastric submucosa rather than mucosa (p = 0.012). Existence of lymph node or distant metastases decreased the survival rates (both p < 0.001). Total gastrectomy, pancreatic resection, and extended D2 lymph node dissection increased the complication rate, but did not have effect on survival. CONCLUSION: The overall prognosis of EGC is favorable. The survival rates of EGC decreased when the tumor was located in the upper part of the stomach or was of mixed histological type, or the patient had lymph node or distant metastasis.


Sujet(s)
Adénocarcinome/chirurgie , Gastrectomie , Tumeurs de l'estomac/chirurgie , Adénocarcinome/mortalité , Adénocarcinome/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Finlande/épidémiologie , Gastrectomie/effets indésirables , Gastrectomie/méthodes , Gastrectomie/mortalité , Humains , Mâle , Adulte d'âge moyen , Pronostic , Tumeurs de l'estomac/mortalité , Tumeurs de l'estomac/anatomopathologie , Analyse de survie , Taux de survie , Facteurs temps , Résultat thérapeutique
7.
Scand J Immunol ; 67(1): 95-102, 2008 Jan.
Article de Anglais | MEDLINE | ID: mdl-18028288

RÉSUMÉ

We explored whether episodes stimulating leucocytes in vivo could be tracked from whole blood samples by monitoring activation of STAT1 by flow cytometry. The method was tested in hepatitis C patients (n = 9) that were on interferon (IFN)alpha regimen. CD14+ monocytes responded strongly to IFNalpha/gamma being sensitive indicators for recent immune activation. At 45 min after s.c. IFNalpha 91% of monocytes were phosphorylated STAT1+. The frequency of responding cells decreased to a base level within 6 h. Monocytes, however, had a long-term deficient phosphorylated STAT1 response to IFNalphain vitro that in patients on standard IFNalpha regimen lasted for 48 h. In patients on pegylated IFNalpha the phosphorylated STAT1 response was completely absent. We conclude that whole blood analysis of STAT1 activation by flow cytometry is applicable to monitor immune cells in patient material.


Sujet(s)
Cytométrie en flux/méthodes , Interféron alpha/usage thérapeutique , Monitorage immunologique , Monocytes/métabolisme , Facteur de transcription STAT-1/métabolisme , Adulte , Animaux , Femelle , Hépatite C/immunologie , Hépatite C/métabolisme , Hépatite C/thérapie , Humains , Mâle , Souris , Adulte d'âge moyen , Monitorage immunologique/méthodes , Monocytes/immunologie , Phosphorylation , Facteur de transcription STAT-1/sang
8.
Scand J Surg ; 96(1): 35-40, 2007.
Article de Anglais | MEDLINE | ID: mdl-17461310

RÉSUMÉ

BACKGROUND: Clinical benefit from extended lymphadenectomy for gastric cancer remains controversial as a considerable variation exists between results of different studies. METHODS: 562 patients were treated at HUCH between 1987-2003, whereof 223 underwent gastrectomy with curative intent. Of these, 114 patients underwent subtotal/total gastrectomy with D1 (standard) lymphadenectomy and 109 patients had D2-3 (extended) lymph node dissection. The clinical outcome of these patients was analysed retrospectively. RESULTS: The incidence of surgical complications was 33.0% in D2-3 and 16.8% in D1 lymphadenectomy groups (p = 0.008). Abscess was the most common complication (11.0%) among D2-3 operated patients and haemorrhage (4.4%) in D1 group. Hospital mortality was 3.7% in D2-3 and 1.8% in D1 group (p = 0.438). The only statistically significant factor influencing the rate of complications was D2-3 lymphadenectomy (OR 2.620, 95% C.I. 1.375 to 4.991). D2-3 was associated with a longer postoperative hospital stay and operation time, greater blood loss and increased need for blood transfusions compared to D1. The 5-year survival was not statistically different between lymphadenectomy groups. CONCLUSION: It is justified to perform a D2-3 gastrectomy in Europe with a acceptable postoperative mortality but with a significant morbidity. Further studies are needed to assess the value of extended lymphadenectomy in gastric cancer.


Sujet(s)
Adénocarcinome/chirurgie , Gastrectomie/méthodes , Lymphadénectomie/méthodes , Tumeurs de l'estomac/chirurgie , Adénocarcinome/mortalité , Adénocarcinome/anatomopathologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Finlande/épidémiologie , Études de suivi , Mortalité hospitalière/tendances , Humains , Mâle , Adulte d'âge moyen , Complications postopératoires/épidémiologie , Prévalence , Études rétrospectives , Tumeurs de l'estomac/mortalité , Tumeurs de l'estomac/anatomopathologie , Taux de survie/tendances , Résultat thérapeutique
9.
Surg Endosc ; 20(4): 603-7, 2006 Apr.
Article de Anglais | MEDLINE | ID: mdl-16424988

RÉSUMÉ

BACKGROUND: This study aimed to assess the effectiveness of therapeutic endoscopy in the treatment of pancreatic pseudocysts, and to define factors limiting endoscopic therapy. METHODS: The results of therapeutic endoscopy were evaluated for 170 patients with pancreatic pseudocysts treated at the Department of Surgery, Helsinki University Central Hospital, during the 6-year period from 1998 to 2003. RESULTS: The therapeutic endoscopy success rate was 86.1%, with 23 (13.9%) patients requiring operative treatment because therapeutic endoscopy was unsuccessful or technically impossible. There was little morbidity and no procedure-related mortality. The majority of the 38 complications, which arose from 380 procedures, could be treated conservatively. CONCLUSIONS: Endoscopic methods are safe and effective for the treatment of pancreatic pseudocysts. The indications for surgery include inaccessible pancreatic duct, location, or content of the pseudocyst rendering the problem not amenable to endoscopic therapy, as well as complications of the endoscopic treatment.


Sujet(s)
Endoscopie digestive , Pseudokyste du pancréas/chirurgie , Adulte , Sujet âgé , Procédures de chirurgie digestive , Drainage , Endoscopie digestive/effets indésirables , Femelle , Études de suivi , Humains , Infections/complications , Mâle , Adulte d'âge moyen , Conduits pancréatiques , Pseudokyste du pancréas/microbiologie , Pseudokyste du pancréas/anatomopathologie , Récidive , Réintervention , Études rétrospectives , Résultat thérapeutique
10.
J Intern Med ; 259(2): 209-13, 2006 Feb.
Article de Anglais | MEDLINE | ID: mdl-16420550

RÉSUMÉ

Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disorder characterized by periodic attacks of fever and inflammation, due to mutations in the gene coding for the TNF type I receptor (TNFRSF1A). A 16-year-old patient with the diagnosis of TRAPS was admitted to hospital because of fever and abdominal pain. Initially, the symptoms were interpreted as manifestations of another TRAPS attack, but the patient's condition worsened, despite treatment with corticosteroids and antibiotics. A repeated computer tomography revealed an intra-abdominal abscess, which necessitated urgent surgical intervention. This case stresses the importance of differential diagnostic vigilance when dealing with patients with rare genetic diseases.


Sujet(s)
Abcès abdominal/complications , Fièvre méditerranéenne familiale/complications , Récepteur au facteur de nécrose tumorale de type I/génétique , Abcès abdominal/imagerie diagnostique , Abcès abdominal/métabolisme , Adolescent , Diagnostic différentiel , Urgences , Fièvre méditerranéenne familiale/imagerie diagnostique , Fièvre méditerranéenne familiale/métabolisme , Femelle , Humains , Récepteur au facteur de nécrose tumorale de type I/métabolisme , Tomodensitométrie , Facteur de nécrose tumorale alpha/métabolisme
11.
Article de Anglais | MEDLINE | ID: mdl-16115753

RÉSUMÉ

The biological roles of intron 1 retaining cyclooxygenase (Cox) 1 splice variants Cox-3 and PCox-1a (Cox-1ir) are not known. In humans, Cox-3 transcription has previously been shown to occur in the brain and in the aorta. However, conclusive evidence regarding the existence of a human Cox-3 protein is lacking. We studied the expression of intron 1 retaining cyclooxygenase 1 splice variants in the human colon cancer cell line Caco-2 and in human colonic tissue samples. In Caco-2 cells, their transcription was induced up to 47-fold by osmotic stress. The corresponding protein, however, could not be detected by Western blotting. In human colonic tissue samples derived from intact and inflamed areas, a low level of Cox-1ir mRNA (1500 +/- 1280 copies per 100 ng total RNA; mean+/-standard deviation; n = 20) was also found. In Caco-2 cells, induction of Cox-1ir under osmotic stress was reversed by addition of the organic osmolyte betaine. Under hypertonic but not under isotonic conditions, splice variant-specific degradation of Cox-1ir mRNA using RNA interference resulted in increased production of fully spliced Cox-1 and Cox-2 mRNA (P = 0.002). In summary, our results indicate that the intron 1 retaining Cox-1 splice variant RNA molecules are expressed by human intestinal epithelial cells in a controlled manner, are most likely not translated and play a regulatory role in the cyclooxygenase mediated epithelial osmoregulation.


Sujet(s)
Épissage alternatif/génétique , Tumeurs colorectales/enzymologie , Cyclooxygenase 1/génétique , Cellules épithéliales/métabolisme , Variation génétique , Prostaglandin-endoperoxide synthases/génétique , Cellules Caco-2 , Cyclooxygenase 2/génétique , Régulation de l'expression des gènes codant pour des enzymes , Humains , Introns , Pression osmotique , ARN messager/génétique
12.
Scand J Surg ; 94(2): 118-23, 2005.
Article de Anglais | MEDLINE | ID: mdl-16111093

RÉSUMÉ

Acute pancreatitis is a common digestive disease of which the severity may vary from mild, edematous to severe, necrotizing disease. An improved outcome in the severe form of the disease is based on early identification of disease severity and subsequent focused management of these high-risk patients. However, the ability of clinicians to predict, upon presentation, which patient will have mild or severe acute pancreatitis is not accurate. Prospective systems using clinical criteria have been used to determine severity in patients with acute pancreatitis, such as the Ranson's prognostic signs, Glasgow score, and the acute physiology and chronic health evaluation II score (APACHE II). Their application in clinical practise has been limited by the time delay of at least 48 h to judge all parameters in the former two and by being cumbersome and time-consuming in the latter. Contrast-enhanced computed tomography is presently the most accurate non-invasive single method to evaluate the severity of acute pancreatitis. It cannot, however, be performed to all patients with acute pancreatitis. Therefore, considerable interest has grown in the development of reliable biochemical markers that reflect the severity of acute pancreatitis. In this article we critically appraise current and new severity markers of acute pancreatitis in their ability to distinguish between mild and severe disease and their clinical utility.


Sujet(s)
Pancréatite/diagnostic , Maladie aigüe , Protéine C-réactive/analyse , Calcitonine/sang , Cytokines/analyse , Indicateurs d'état de santé , Humains , Oligopeptides/urine , Peptides/sang , Précurseurs de protéines/sang , Protéines/analyse , Trypsine/sang , Trypsinogène/sang
13.
J Cell Physiol ; 204(3): 800-7, 2005 Sep.
Article de Anglais | MEDLINE | ID: mdl-15795937

RÉSUMÉ

The impairment of angiogenesis in aging has been attributed, in part, to alterations in proteins associated with the extracellular matrix (ECM). SPARC (secreted protein acidic and rich in cysteine/osteonectin/BM-40) is a matricellular protein that regulates endothelial cell function as well as cell-ECM interactions. We have previously shown that angiogenesis, as reflected by fibrovascular invasion into subcutaneously implanted polyvinyl alcohol (PVA) sponges, is increased in SPARC-null mice (6-9 months of age) relative to their wild-type (WT) counterparts. In this study, we define the influence of aging on (a) the expression of SPARC and (b) fibrovascular invasion into sponge implants in SPARC-null and WT mice. The expression of SPARC in fibroblasts and endothelial cells derived from young donors (humans mean age less than 30 years and mice 4-6 months of age) and old donors (humans mean age over 65 years and mice 22-27 months of age) decreased 1.6 to 2.3-fold with age. Analysis of fibrovascular invasion into sponges implanted into old (22-27 months) SPARC-null and WT mice showed no differences in percent area of invasion or collagenous ECM. Moreover, sponges from old SPARC-null and WT mice contained similar levels of VEGF that were significantly lower than those from young (4-6 months) mice. In contrast to fibroblasts from young SPARC-null mice, dermal fibroblasts from old SPARC-null mice did not migrate farther, proliferate faster, or produce greater amounts of VEGF relative to their old WT counterparts. However, when stimulated with TGF-beta1, primary cells isolated from the sponge implants, and dermal fibroblasts from both old SPARC-null and WT mice, showed marked increases in VEGF secretion. These data indicate that aging results in a loss of enhanced angiogenesis in SPARC-null mice, as a result of the detrimental impact of age on cellular functions, collagen deposition, and VEGF synthesis. However, the influence of aging on these processes may be reversed, in part, by growth factor stimulation.


Sujet(s)
Vieillissement/physiologie , Néovascularisation physiologique/physiologie , Ostéonectine/déficit , Adulte , Sujet âgé , Animaux , Mouvement cellulaire , Cellules cultivées , Collagène/métabolisme , Matrice extracellulaire/métabolisme , Fibroblastes/métabolisme , Délétion de gène , Régulation de l'expression des gènes , Humains , Mâle , Souris , Souris knockout , Ostéonectine/biosynthèse , Ostéonectine/génétique , Poly(alcool vinylique) , Peau/cytologie , Peau/métabolisme , Éponges chirurgicales , Facteur de croissance transformant bêta/pharmacologie , Facteur de croissance transformant bêta-1 , Facteur de croissance endothéliale vasculaire de type A/métabolisme
14.
Br J Surg ; 92(1): 68-75, 2005 Jan.
Article de Anglais | MEDLINE | ID: mdl-15521080

RÉSUMÉ

BACKGROUND: Several biological markers and clinical scoring systems have been used to predict the course of acute pancreatitis. Because organ failure is the most severe complication of the disease, prognostic markers and their combinations that would predict organ failure on hospital admission were sought. METHODS: Some 351 consecutive patients with acute pancreatitis were studied. Blood samples were taken within 12 h of admission. This case-control study included all 33 patients with organ failure and 99 matched controls without organ failure. Measurements included 19 prognostic markers and Acute Physiology And Chronic Health Evaluation (APACHE) II score. RESULTS: Plasma interleukin 10, serum glucose and serum calcium were identified as independent predictors of organ failure by logistic regression analysis. Calcium level correlated with clinical onset of organ failure. The combination of interleukin 10 (more than 50 pg/ml) or calcium (less than 1.65 mmol/l) was a significantly better predictor than any single marker or APACHE II score, with a sensitivity of 88 per cent, specificity 93 per cent and diagnostic odds ratio 94. CONCLUSION: Organ failure in acute pancreatitis can be predicted with high accuracy at hospital admission using a combination of plasma interleukin 10 and serum calcium measurements.


Sujet(s)
Glycémie/analyse , Calcium/sang , Interleukine-10/sang , Défaillance multiviscérale/diagnostic , Pancréatite/complications , Indice APACHE , Maladie aigüe , Adulte , Marqueurs biologiques/sang , Études cas-témoins , Diagnostic précoce , Femelle , Hospitalisation , Humains , Mâle , Adulte d'âge moyen , Défaillance multiviscérale/étiologie , Pancréatite/sang , Pronostic , Analyse de régression , Sensibilité et spécificité
15.
Scand J Gastroenterol ; 39(11): 1095-104, 2004 Nov.
Article de Anglais | MEDLINE | ID: mdl-15545168

RÉSUMÉ

BACKGROUND: Matrix metalloproteinases (MMPs) play a crucial role in wound healing of the skin, airways, and cornea, but data on MMPs in normal intestinal wound healing is limited. The aim of this study was to clarify the role of collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) in intestinal wound repair and to determine the effect of cytokines on the expression of these MMPs in intestinal epithelial cell lines. METHODS: Surgical specimens from patients with ischemic colitis (n = 5) were used as an in vivo model of intestinal re-epithelialization. Fetal ileal explants were used as an ex vivo model. In situ hybridization for MMPs -1, -3, -7, and -10 was performed and immunohistochemical stainings were used to localize MMP-7 and -9 expressing cells. Stainings for cytokeratin and laminin-5 were performed to identify epithelial cells and migrating enterocytes, respectively. Caco-2, HT-29, and WiDr cell lines were treated for 6-48 h with different cytokines (e.g. EGF, KGF, IL-1 beta, TGF-alpha, TNF-alpha, and TGF-beta1) and Taqman real-time quantitative RT-PCR was used to investigate their effect on the expression of MMPs-1, -7, and -10. RESULTS: MMP-7, MMP-10, and MMP-1 were expressed by migrating enterocytes bordering intestinal ulcers in 5/5, 3/5, and 3/5 samples, respectively. In the fetal gut model, MMP-1 and MMP-10 were expressed by migrating enterocytes, but matrilysin-1 expression was not detected. Matrilysin-1 was up-regulated by TNF-alpha and IL-1 beta, and stromelysin-2 by TNF-alpha and EGF in Caco-2 and WiDr cell cultures. MMP-1 was up-regulated in Caco-2 cells by TGF-beta, EGF, and IL-1 beta, but only by EGF in WiDR cells. CONCLUSIONS: It is concluded that collagenase-1, stromelysin-2, and matrilysin-1 are involved in intestinal re-epithelialization in vivo and that they are up-regulated by cytokines relevant in wound repair.


Sujet(s)
Entérocytes/enzymologie , Matrix metalloproteinases/métabolisme , Cicatrisation de plaie , Lignée cellulaire , Mouvement cellulaire , Colite ischémique/enzymologie , Cytokines/pharmacologie , Entérocytes/physiologie , Femelle , Foetus , Humains , Iléum/métabolisme , Iléum/physiologie , Immunohistochimie , Maladies intestinales/enzymologie , Maladies intestinales/anatomopathologie , Mâle , Matrix metalloproteinase 1/métabolisme , Matrix metalloproteinase 10 , Matrix metalloproteinase 7/métabolisme , Metalloendopeptidases/métabolisme , Adulte d'âge moyen , RT-PCR , Ulcère/métabolisme , Régulation positive
16.
Br J Surg ; 91(8): 1027-33, 2004 Aug.
Article de Anglais | MEDLINE | ID: mdl-15286966

RÉSUMÉ

BACKGROUND: Trypsinogen activation peptide (TAP) may be an early marker of severe pancreatitis. Previous studies have included all patients with organ failure in the group with severe pancreatitis, although patients with transient organ failure may have a good prognosis. The aim of this study was to determine the value of urinary TAP estimation for prediction of severity of acute pancreatitis, and to validate use of several markers of prediction of severity against a new, stringent definition of severity. METHODS: Patients with acute pancreatitis were recruited within 24 h of onset of symptoms. Urine and blood samples were collected for 24 h, and Acute Physiology And Chronic Health Evaluation (APACHE) II (24 h), Ranson (48 h) and Glasgow (48 h) scores were calculated. Severe acute pancreatitis was defined by the presence of a local complication or the presence of organ failure for more than 48 h. RESULTS: Urinary TAP levels were significantly greater in patients with severe pancreatitis than in those with mild disease during the first 36 h of admission. The highest of three estimations of TAP in the first 24 h was as effective as APACHE II at 24 h in predicting severity. At 24 h after admission, urinary TAP was better than C-reactive protein (CRP) in predicting severity. The combination of TAP and CRP at 24 h allowed identification of high- and low-risk groups. The new definition of severity excluded 24 of 190 patients with transient organ failure; none of these patients died. CONCLUSION: Use of TAP improved early prediction of the severity of acute pancreatitis. Organ failure that resolves within 48 h does not signify a severe attack of acute pancreatitis.


Sujet(s)
Oligopeptides/urine , Pancréatite/diagnostic , Indice APACHE , Maladie aigüe , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/urine , Femelle , Humains , Mâle , Adulte d'âge moyen , Valeur prédictive des tests , Pronostic , Courbe ROC
17.
Dig Dis Sci ; 49(4): 653-61, 2004 Apr.
Article de Anglais | MEDLINE | ID: mdl-15185874

RÉSUMÉ

Several matrix metalloproteinases (MMPs) have been implicated in intestinal inflammation, mucosal wound healing, and cancer progression. The purpose of this study was to examine the cellular location and putative function of MMP-19, MMP-26 (matrilysin-2), and MMP-28 (epilysin), in normal, inflammatory, and malignant conditions of the intestine. Peroperative tissue specimens from patients with ulcerative colitis (UC) (n = 16) and archival tissue samples of ischemic colitis (n = 9), Crohn's disease (n = 7), UC (n = 8), colon cancer (n = 20), and healthy intestine (n = 5) were examined using immunohistochemical analyses with polyclonal antibodies. Unlike many classical MMPs, MMP-19, MMP-26, and MMP-28 were all expressed in normal intestine. In inflammatory bowel disease (IBD), MMP- 19 was expressed in nonmigrating enterocytes and shedding epithelium. MMP-26 was detected in migrating enterocytes, unlike MMP-28. In colon carcinomas, MMP-19 and MMP-28 expression was downregulated in tumor epithelium. Staining for MMP-26 revealed a meshwork-like pattern between cancer islets, which was absent from most dedifferentiated areas. Our results suggest that MMP-19 is involved in epithelial proliferation and MMP-26 in enterocyte migration, while MMP-28 expression is not associated with inflammatory and destructive changes seen in IBD. In contrast to many previously characterized MMPs, MMP-19 and MMP-28 are downregulated during malignant transformation of the colon and may play a prominent role in tissue homeostasis.


Sujet(s)
Rectocolite hémorragique/anatomopathologie , Tumeurs du côlon/anatomopathologie , Maladie de Crohn/anatomopathologie , Matrix metalloproteinases/analyse , Metalloendopeptidases/analyse , Marqueurs biologiques/analyse , Mouvement cellulaire , Études de cohortes , Rectocolite hémorragique/métabolisme , Tumeurs du côlon/métabolisme , Maladie de Crohn/métabolisme , Techniques de culture , Régulation négative , Femelle , Humains , Immunohistochimie , Mâle , Secreted matrix metalloproteinases , Probabilité , Pronostic , Valeurs de référence , Sensibilité et spécificité
18.
Arch Virol ; 149(6): 1095-106, 2004 Jun.
Article de Anglais | MEDLINE | ID: mdl-15168197

RÉSUMÉ

TT virus (TTV) is a newly discovered human virus of high genotypic diversity. TTV is widely distributed among humans, but the possible genotype-related differences in TTV biology are not well known. The prevalence and amount of TTV-DNA, especially of genotype 6, was determined by nested-PCR in various human tissues, and human parvovirus B19, another ssDNA virus, was used as a reference. TTV DNA was detected simultaneously in bile, peripheral blood mononuclear cells (PBMC) and plasma of 77% subjects, in 38% skin samples, in 38% synovial samples and in all (100%) adenoids, tonsils and liver samples. The relative concentrations of TTV-DNA did not vary significantly among the different samples. Genotype 6 TTV-DNA was detected in bile and plasma of one subject (3%), in skin and serum of one subject (8%) and in one liver (5%). The overall prevalence of TTV genotype 6 was 4% in subjects and 4% in sera. TTV genotype 6 was shown to occur in human tissues with no obvious tissue-type or symptom specificity. Parvovirus B19 DNA was detected overall in 38% subjects, and bile was the only sample type tested that did not persistently harbour B19 DNA.


Sujet(s)
ADN viral/analyse , Virus torque teno/isolement et purification , Adulte , Sujet âgé , Bile/virologie , Sang/virologie , Infections à virus à ADN/sang , Infections à virus à ADN/épidémiologie , Infections à virus à ADN/virologie , ADN viral/sang , Femelle , Finlande/épidémiologie , Génotype , Humains , Foie/virologie , Tissu lymphoïde/virologie , Mâle , Adulte d'âge moyen , Réaction de polymérisation en chaîne , Prévalence , Peau/virologie , Synovie/virologie , Virus torque teno/génétique
19.
Scand J Gastroenterol ; 39(2): 104-10, 2004 Feb.
Article de Anglais | MEDLINE | ID: mdl-15000270

RÉSUMÉ

BACKGROUND: Ethanol is a well-established 'barrier breaker' in gastric mucosa, but its effects at cellular level remain to be detailed. METHODS: Gastric epithelial cells were isolated from rabbits and cultured to monolayers. Intracellular calcium was measured spectrofluorometrically with fura-2. The patency of gap junctions was assessed by photobleaching a small area of 5-carboxyfluorescein loaded monolayer and measuring recovery of fluorescence. For cell volume measurements the change in fluorescence intensity was followed in calcein-loaded monolayers with a confocal microscope. RESULTS: Intracellular calcium concentration was increased from 65 +/- 9 to 140 +/- 17 nM; recovery of fluorescence signal after photobleaching was diminished from 53% +/- 11% to 9% +/- 3%; and cell volume was decreased significantly after 10 min exposure to 5% (vol/vol) ethanol. This volume decrease was prevented with serosal application of the potassium channel blocker, quinine, or by blocking the intracellular calcium signalling pathway with the intracellular calcium-chelating agent BAPTA. This suggests that luminal ethanol opens the basolateral calcium-dependent potassium selective channels via calcium signalling pathway, with resultant shrinkage of the cell. CONCLUSION: Intracellular calcium concentration is increased, gap junctions are closed and cell volume is decreased after exposure to 5% ethanol. Since gap junctions are known to be calcium gated, it is likely that their closure is secondary to the elevated cytosolic calcium in ethanol injured cells. This may have a protective function by limiting intercellular spread of impending cell injury. The opening of the basolateral potassium channel probably underlies the ethanol-induced cell shrinkage and might contribute to the ethanol-provoked epithelial damage.


Sujet(s)
Signalisation calcique/effets des médicaments et des substances chimiques , Calcium/métabolisme , Éthanol/pharmacologie , Jonctions communicantes/effets des médicaments et des substances chimiques , Muqueuse gastrique/effets des médicaments et des substances chimiques , Animaux , Taille de la cellule/effets des médicaments et des substances chimiques , Cellules cultivées , Cellules épithéliales/effets des médicaments et des substances chimiques , Concentration osmolaire , Lapins
20.
Scand J Gastroenterol ; 39(2): 178-87, 2004 Feb.
Article de Anglais | MEDLINE | ID: mdl-15000282

RÉSUMÉ

BACKGROUND: Immune suppression plays a role in the pathogenesis of acute pancreatitis. The purpose was to describe plasma anti-inflammatory cytokines and blood monocyte human leucocyte antigen (HLA)-DR expression, a cellular marker of immune suppression, in relation to clinical outcome in acute pancreatitis. METHODS: We studied 74 patients with acute pancreatitis admitted within 72 h after symptom onset; 27 had mild disease and 47 severe disease, of whom 20 developed organ failure. Plasma cytokine concentrations and monocyte HLA-DR density were determined at admission and 1, 2, 3, 7, 14 and 21 days later. RESULTS: The levels of interleukin-1 receptor antagonist, interleukin-6 and interleukin-10 correlated inversely to monocyte HLA-DR expression; each marker correlated with disease severity. Interleukin-4, -11 and -13 levels were low. Organ failure occurred at median 36 h (range 8 to 158) after admission and was predicted at admission by the combination of interleukin-6 and interleukin-10 with sensitivity of 95%, specificity of 88% and positive likelihood ratio of 7.6 (95% confidence interval 3.3 to 17). Patients with secondary infections had a lower proportion of HLA-DR positive monocytes than did controls at day 14 (median: 32% versus 65%; n = 7) and at day 21 (median: 49% versus 83%; n = 6), P < 0.05 each. In the organ failure group, HLA-DR expression did not differ between survivors and non-survivors. CONCLUSIONS: Determining the severity of anti-inflammatory reaction at admission and monitoring the course of immune suppression provide a means for predicting clinical outcome in acute pancreatitis.


Sujet(s)
Antigènes HLA-DR/sang , Interleukines/sang , Pancréatite/sang , Maladie aigüe , Femelle , Cytométrie en flux , Humains , Mâle , Défaillance multiviscérale/étiologie , Pancréatite/complications , Pancréatite/immunologie , Pronostic , Courbe ROC , Indice de gravité de la maladie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE